PATENT CLAIM ANALYSIS

Application Number: 16033953
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-11
Patent Classification: ["514", "377000"]

Abstract:
The present invention relates to pharmaceutical compositions for treating cancer comprising BRAF inhibitors, (e.g. vemurafenib) and/or MEK inhibitor, (e.g. trametinib, RO5068760), in combination with anti-tubulin compounds of the invention or other known tubulin inhibitors, and using such compositions for treating cancer such as melanoma, drug-resistant cancer, and cancer metastasis.

Claim (Index 1):
A method of treating, suppressing, reducing the severity, reducing the risk, or inhibiting BRAF mutant cancer in a subject, comprising administering a composition comprising at least one of a BRAF inhibitor or a MEK inhibitor, in combination with a compound represented by the structure of formula II: wherein\n A is single or fused aromatic or heteroaromatic ring system; \n R 1  is H, C 1 -C6 linear or branched alkyl, aryl, phenyl, benzyl, haloalkyl, aminoalkyl, \u2014OCH 2 Ph, SO 2 -aryl, SO 2 -phenyl, \u2014(C\u2550O)-aryl, \u2014(C\u2550O)-phenyl or OH; \n R 4  and R 5  are each independently hydrogen, C 1 -C 6  linear or branched alkyl, C 1 -C 6  linear or branched haloalkyl, C 1 -C 6  linear or branched alkoxy, C 1 -C 6  linear or branched haloalkoxy, F, Cl, Br, I, CF 3 , CN, \u2014CH 2 CN, NH 2 , OH, \u2014OC(O)CF 3 , alkylamino, aminoalkyl, \u2014OCH 2 Ph, \u2014NHCO-alkyl, COOH, \u2014C(O)Ph, C(O)O-alkyl, C(O)H, \u2014C(O)NH 2  or NO 2 ; and \n n is an integer between 1-4; \n or its pharmaceutically acceptable salt, N-oxide, hydrate, tautomer or isomer; in combination with at least one of a BRAF inhibitor or a MEK inhibitor; and a pharmaceutically acceptable carrier.

Metadata:
- Claim Count in Document: 3.0
- Percentile: 95.0
- Lexical Diversity: 1.5
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13676650', '13216927', '12981233', '14049950', '14692597']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8055614635641276
- 35 USC 102 Novelty (BERT): 0.5600130890925138
- Combined Prediction Score: 0.7810066261169663
- Mean Citation Score: 433.06619600000016
- Max Citation Score: 478.3542
- Similarity Product: 328.72087667963507

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test